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Abstract
Objective : Ovarian torsion is an acute gynecological condition. Torsion is more likely to occur 
with benign rather than malignant tumors. Mature cystic teratoma of the ovary (MCTO) is fre-
quent in women of reproductive age ; however, the incidence of malignant transformation is approxi-
mately 2%. We report a case of malignant transformation of MCTO presenting as ovarian tumor 
torsion.
Case report : A 51-year-old premenopausal woman was diagnosed with mature cystic teratoma in 
the left ovary 7 years ago. The patient visited our hospital because she had been experiencing of 
pain in left lower abdomen for the past two days. She was diagnosed with ovarian tumor torsion 
and underwent emergency surgery. The left ovarian tumor was twisted, and left salpingo-oopho-
rectomy was performed. Histopathological examination revealed squamous cell carcinoma arising 
from the MCTO. We carefully followed the patients without performing staging laparotomy. On 
postoperative day 112, multiple lymph node metastases in the pelvic and para-aortic areas were 
found by positron-emission tomography and computed tomography. After referral to a university 
hospital, total hysterectomy, right salpingo-oophorectomy, partial omentectomy, and pelvic and para-
aortic lymphadenectomy were performed. Metastases of squamous cell carcinoma were confirmed 
in the pelvic and para-aortic lymph nodes. Six courses of adjuvant chemotherapy with paclitaxel 
and carboplatin were given following radical surgery to prevent the recurrence of malignant trans-
formation of MCTO. No recurrence of the disease has been observed during 2 years of follow-up.
Conclusion : When physicians diagnose large ovarian tumor torsion cases, preoperative examina-
tions should be performed, with the possibility of malignancy in mind.
Key words : acute abdomen, ovarian torsion, mature cystic teratoma, malignant transformation, 
squamous cell carcinoma
Introduction
Ovarian tumor torsion is an acute gynecological 
condition that requires emergency surgery. Tor-
sion is more likely to occur with benign rather than 
malignant tumors1-3). Mature cystic teratoma of the 
ovary (MCTO) is a benign tumor that is frequently 
observed in women of reproductive age. However, 
malignant transformation occurs in <2% of 
MCTO4). Here, we report a woman with malignant 
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transformation of MCTO, which was presented as 
ovarian tumor torsion, and review the literature.
Case presentation
A 51-year-old premenopausal woman gravida 3, 
para 3, was diagnosed with left MCTO 7 years 
ago. The size of the MCTO was 59 mm at the time 
of diagnosis. She underwent regular ovarian exam-
ination for 2 years after the diagnosis but had not 
visited the hospital for 5 years. She had a history 
of appendectomy at 7 years of age and received 
medication for hyperthyroidism since she was 37 
years old. She experienced left lower abdominal 
pain for 2 days and visited the hospital due to in-
creasing pain. Physical examination showed a flat 
abdomen with tenderness around the left lower ab-
domen. A solid tumor was palpable by bimanual 
examination on the left side. Transvaginal ultraso-
nography revealed a 91-mm cystic and solid ovarian 
mass on the left ovary (Fig. 1). She was diagnosed 
with ovarian tumor torsion and had to undergo 
emergency surgery. Height, weight, and body mass 
index (BMI) were 165 cm, 96 kg, and 35.3 kg/m2, re-
spectively. Body temperature was within the nor-
mal range, pulse rate was 84 beats/min, and blood 
pressure was 121/55 mmHg. Peripheral blood ex-
amination showed that the white blood cell count 
was 8,820/µL, red blood cell count was 4.65 × 106/
µL, hemoglobin was 12.1 g/dL, and hematocrit was 
37.5%. Biochemical data revealed that the C-reac-
tive protein level was as high as 13.9 mg/dL. Lev-
els of tumor makers, namely serum α-fetoprotein, 
carbohydrate antigen 19-9 (CA19-9), CA125, and 
squamous cell carcinoma (SCC) antigen were 4.0 ng/
mL (reference, <10.0 ng/mL), < 2.0 U/mL (refer-
ence, < 37.0 U/mL), 84.1 U/mL (reference, < 35.0 
U/mL), and 1.4 ng/mL (reference, < 1.5 ng/mL), re-
spectively. Laparotomy was immediately per-
formed. Operative findings showed 360° torsion of 
the left ovarian tumor without ascites in the pelvic 
cavity. There were no sign of congestion and rup-
ture on the surface of the twisted ovary. The uter-
us and right ovary appeared normal. Left salpingo-
oophorectomy was performed. The duration of 
operation was 54 min, and the volume of blood loss 
was 30 mL. The diameter of the extirpated ovarian 
tumor was 11 cm, and the tumor contained fat and 
hair. Histopathological findings showed both com-
ponents of mature cystic teratoma and SCC with 
marked nuclear and cellular atypia in the solid part 
(Fig. 2). The pathological diagnosis was malignant 
transformation with SCC of MCTO. We recom-
mended staging laparotomy to determine the treat-
ment strategy. The patient refused to undergo the 
procedure ; subsequently, a strict follow-up for 
stage IA ovarian cancer was conducted. The pa-
tient was discharged from the hospital 10 days post 
Fig. 1. Transvaginal ultrasonographic findings at onset of ovarian torsion
  Transvaginal ultrasonography revealed a 91-mm cystic and solid ovarian mass on the left adnexal lesion.
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operation. On postoperative day 112, the serum 
CA125 level was as high as 101.4 U/mL. Positron-
emission tomography and computed tomography 
(CT) showed some nodal lesions with remarkable 
uptake of 18F-fluorodeoxy glucose (Fig. 3). She 
was referred to a university hospital due to cancer 
recurrence. Her BMI was as high as 37.8 kg/m2, 
and biochemical examination showed that she had 
hyperlipidemia and diabetes mellitus. The serum 
CA125, SCC antigen, CA19-9, and carcinoembryonic 
antigen (CEA) levels were 216 U/mL (reference, 
< 35.0 U/mL), 2.0 ng/mL (reference, < 1.5 ng/mL), 
< 2.0 U/mL (reference, < 37.0 U/mL), and 3.5 ng/
mL (reference, < 5.0 ng/mL), respectively. The 
patient underwent radical surgery with total abdomi-
nal hysterectomy, right salpingo-oophorectomy, par-
tial omentectomy, and pelvic and para-aortic lymph 
node dissection. Operative findings revealed that 
there was no ascites or dissemination in the abdomi-
nal cavity ; no metastatic lesion was found in the 
uterus and right adnexa. The enlarged pelvic and 
para-aortic lymph nodes were removed. Thereaf-
ter, complete surgical treatment was achieved. The 
duration of operation was 360 min, and the volume 
of blood loss was 370 mL. Histopathological exam-
ination showed positive lymph nodes with SCC. 
The numbers of positive/total resected lymph nodes 
in the left obturator, left external iliac, and para-aor-
tic nodes were 1/5, 2/7, and 1/1, respectively. Im-
munostaining was performed to assess whether the 
tumor cells were of epithelial or germ cell origin 
(Table 1) ; the results confirmed recurrence of the 
malignant transformation of MCTO with SCC (Fig. 
4). The postoperative course was uneventful, and 
the patient was discharged 10 days post-op. She 
received 6 courses of conventional paclitaxel and 
carboplatin as adjuvant chemotherapy. She has had 
no recurrence for 2 years after treatment. The 
treatment course is shown in Fig. 5.
Discussion
Ovarian tumor torsion is more likely to occur 
with benign rather than malignant tumors. The ac-
tual incidence of adnexal mass torsion is un-
known. Two studies reported that ovarian torsion 
Fig. 2. Histopathological findings of the left adnexal tumor at the time of initial surgery
 A. Macroscopic appearance of the left ovarian tumor. The arrow indicates the left fallopian tube. B. Histologi-
cal findings of mature cystic teratoma with keratinized epidermis and sebaceous glands (part of “a” of photograph 
A). C and D. Histological findings of squamous cell carcinoma component showing honeycomb-like arrange-
ment with severe nuclear atypia (C, low magnification ; D, high magnification).
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Fig. 3. PET-CT images
 A, B. High accumulation of FDG in the para-aortic lesion (SUVmax = 18.3). A, coronal section ; B, transverse 
section. C, D. High accumulation of FDG in pelvic lymph nodes (SUV max = 14.2). C, coronal section ; D, 
transverse section.
 PET, positron-emission tomography ; CT, computed tomography ; FDG, 18F-fluorodeoxyglucose ; SUVmax, 
maximum standardized uptake value
Fig. 4. Histopathological findings of resected lymph node
 A, B. Resected para-aortic lymph node shows substantial cellular and nuclear atypia (A, low magnification 
(40×) ; B, high magnification (400×).
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accounted for 2.7% of emergency surgeries5) and 
15% of adnexal mass surgeries6). The proportion of 
torsion with malignant ovarian tumors is approxi-
mately 2%1-3). A higher incidence of malignant tu-
mors in cases of torsion was noted in menopausal 
women than in premenopausal women7,8). As ma-
lignant ovarian tumors are less likely to cause tor-
sion, it is assumed that they adhere to adjacent pel-
vic tissue. In this case, however, the tumor did not 
adhere to anything and was twisted. Because 
MCTO, which is a benign tumor, is thought to be 
less likely to cause adhesion, the initial stage of ma-
lignant transformation of MCTO might be prone to 
torsion.
Although MCTO is a benign ovarian tumor that 
represents 20% of all ovarian tumors, it may progress 
to malignancy4). The incidence of malignant transfor-
mation of MCTO is approximately 0.2-2%4,9-12). SCC, 
which arises from the ectoderm, accounts for 80% of 
malignant transformations4,13). Other reported 
types of malignant transformation of MCTO include 
basal cell carcinoma, melanoma, adenocarcinoma, 
thyroid carcinoma, and carcinoid4,13). In this case, it 
was difficult to distinguish between SCC and germ 
cell tumors based on tissue morphology. Immunos-
tains for epithelial and germ cell markers yielded a 
histopathological diagnosis of SCC (Table 1). Im-
munostaining of epithelial markers, such as CK10 
and CK18, are useful in the pathological diagnosis of 
SCC4).
Studies have reported various risk factors for ma-
lignant transformation of MCTO4,13-15) ; including age 
> 45 years, tumor diameter > 10 cm, and high tumor 
marker levels. As far as tumor markers are con-
cerned, serum SCC antigen levels are frequently high 
Fig. 5. Clinical course of treatment
 The solid line indicates the CA125 level. The dotted line indicates the SCC antigen level.
 LSO, left salpingo-oophorectomy ; ATH, abdominal hysterectomy ; RSO, right salpingo-oophorectomy ; PLD, 
pelvic lymphadenectomy ; PAN, para-aortic lymphadenectomy ; pOME, partial omentectomy ; TC, paclitaxel 
and carboplatin
Table 1.  Immunostaining expression of various mark-
ers in resected lymph nodes
Markers of 
epithelial origin 
or others
Markers of germ 
cell origin
Positive staining CK AE1/AE3
EMA
CK5/6
p63
p40
Calponin
BAF47
none
Negative staining CD30
SMA
c-kit
Oct3/4
SALL4
AFP
hCG
CK, cytokeratin ; SMA, smooth muscle actin ; AFP, 
α-fetoprotein ; hCG, human chorionic gonadotropin
49Malignant transformation arising from mature cystic teratoma of the ovary presenting as ovarian torsion
Ta
bl
e 
2.
 
C
as
es
 w
ith
 m
al
ig
na
nt
 tr
an
sf
or
m
at
io
n 
of
 m
at
ur
e 
cy
st
ic
 te
ra
to
m
a 
of
 th
e 
ov
ar
y 
pr
es
en
tin
g 
as
 o
va
ri
an
 tu
m
or
 to
rs
io
n
A
ut
ho
rs
 
(p
ub
lic
at
io
n 
ye
ar
)
A
ge
M
en
o-
pa
us
e
Sy
m
p-
to
m
s
To
r-
si
on
 
si
de
R
up
-
tu
re
A
sc
ite
s
C
on
tr
al
at
-
er
al
 o
va
ry
M
ax
i-
m
al
 
tu
m
or
 
si
ze
 
(c
m
)
E
le
va
te
d 
tu
m
or
 
m
ar
ke
r 
le
ve
ls
In
iti
al
 s
ur
ge
ry
A
b-
do
m
i-
na
l 
cy
to
l-
og
y
R
ap
id
 
pa
th
ol
-
og
y
Pa
th
ol
og
ic
al
 
di
ag
no
si
s
A
dd
iti
on
al
 
tr
ea
tm
en
ts
St
ag
-
in
g
P
ro
gn
os
is
O
ka
no
 e
t a
l. 
(2
00
2)
77
Ye
s
L
A
P,
 A
A
R
ig
ht
N
o
Ye
s,
 b
lo
od
y
N
on
e 
of
 t
he
 
tu
m
or
s
13
N
on
e
B
SO
 
(la
pa
ro
to
m
y)
Ye
s
N
o
M
C
T
 w
ith
 c
ar
ci
-
no
id
N
on
e
N
.A
.
N
.A
.
M
in
 e
t a
l. 
(2
00
6)
77
Ye
s
L
A
P,
 A
A
R
ig
ht
N
o
Ye
s,
 b
lo
od
y
N
on
e 
of
 t
he
 
tu
m
or
s
17
C
A
12
5
AT
H
+
B
SO
 
(la
pa
ro
to
m
y)
Ye
s
N
o
M
C
T
 w
ith
 in
te
s-
ti
na
l 
ad
en
oc
ar
ci
-
no
m
a
N
on
e
N
.A
.
N
E
D
 a
t 
1 
ye
ar
 
af
te
r 
su
rg
er
y
K
or
ko
nt
ze
lo
s 
et
 a
l. 
(2
01
0)
56
Ye
s
L
A
P,
 A
A
R
ig
ht
N
o
N
.A
.
N
on
e 
of
 t
he
 
tu
m
or
s
17
N
.A
.
AT
H
+
B
SO
 
(la
pa
ro
to
m
y)
N
o
N
o
M
C
T
 w
ith
 S
C
C
N
on
e
N
.A
.
N
E
D
 a
t 
4 
ye
ar
s 
af
te
r 
su
rg
er
y
Ta
m
ur
a 
et
 a
l. 
(2
01
3)
55
Ye
s
L
A
P,
 A
A
R
ig
ht
N
o
N
.A
.
M
C
T
 w
it
h 
SC
C
11
C
A
19
-
9,
 
SC
C
, 
C
E
A
B
SO
 
(la
pa
ro
to
m
y)
Ye
s
N
o
M
C
T
 w
ith
 S
C
C
AT
H
+
P
L
D
+
PA
N
+
O
M
E
IA
N
E
D
 a
t 
3 
ye
ar
s 
af
te
r 
su
rg
er
y
N
ag
ao
 e
t a
l. 
(2
01
5)
50
s
Ye
s
L
A
P,
 A
A
R
ig
ht
N
o
N
on
e
M
C
T
 8
hC
G
, 
C
A
19
-
9
B
SO
 
(la
pa
ro
to
m
y)
N
o
N
o
M
C
T
 w
ith
 c
ar
ci
-
no
id
N
on
e
N
.A
.
N
.A
.
Ya
m
ad
a 
et
 a
l. 
(2
01
6)
38
N
.A
.
L
A
P,
 A
A
R
ig
ht
N
o
N
on
e
N
on
e 
of
 t
he
 
tu
m
or
s
 7
SC
C
C
ys
te
ct
om
y 
(la
pa
ro
sc
op
y)
N
o
N
o
M
C
T
 w
ith
 S
C
C
N
on
e
N
.A
.
N
E
D
 a
t 
1
.5
 
ye
ar
s 
af
te
r 
su
r-
ge
ry
C
ok
m
ez
 e
t a
l. 
(2
01
9)
38
N
.A
.
L
A
P,
 A
A
L
ef
t
N
o
N
.A
.
N
on
e 
of
 t
he
 
tu
m
or
s
11
N
on
e
B
SO
 
(la
pa
ro
to
m
y)
N
o
N
o
M
C
T
 w
ith
 p
ap
il-
la
ry
 t
hy
ro
id
 c
ar
-
ci
no
m
a
N
on
e
N
.A
.
N
.A
.
P
r e
se
nt
 c
as
e
51
N
o
L
A
P,
 A
A
L
ef
t
N
o
N
on
e
N
on
e 
of
 t
he
 
tu
m
or
s
11
C
A
12
5,
 
SC
C
L
SO
 
(la
pa
ro
to
m
y)
N
o
N
o
M
C
T
 w
ith
 S
C
C
AT
H
+
R
SO
+
P
L
D
+
PA
N
+
O
M
E
+
ad
ju
va
nt
 
ch
em
ot
he
ra
py
IA
N
E
D
 a
t 
2 
ye
ar
s 
af
te
r 
tr
ea
tm
en
ts
A
T
H
, 
ab
do
m
in
al
 t
ot
al
 h
ys
te
re
ct
om
y
;
B
S
O
, 
bi
la
te
ra
l 
sa
lp
in
go
-
oo
ph
or
ec
to
m
y
;
M
C
T,
 m
at
ur
e 
cy
st
ic
 t
er
at
om
a
;
S
C
C
, 
sq
ua
m
ou
s 
ce
ll
 c
ar
ci
no
m
a
;
P
L
D
, 
pe
lv
ic
 
ly
m
ph
ad
en
ec
to
m
y
;
PA
N
, p
ar
a-
ao
rt
ic
 ly
m
ph
ad
en
ec
to
m
y
;
O
M
E
, o
m
en
te
ct
om
y
;
N
E
D
, n
o 
ev
id
en
ce
 o
f d
is
ea
se
;
N
.A
., 
no
t a
pp
lic
ab
le
50 N. Toba et al.
in patients with SCC arising from MCTO4,13,16-19). 
Levels of other tumor markers, such as serum 
CA125, C19-9, and CEA, are also high in patients 
with various histological types of malignant transfor-
mation of MCTO13,17). In this case, the patient had 
the following risk factors : age > 45 years, tumor 
diameter > 10 cm, and elevated serum CA125.
CT and magnetic resonance imaging (MRI) are 
useful for the preoperative diagnosis of malignant 
transformation of MCTO4). Kido et al. reported the 
MRI findings for malignant transformation of MCTO 
and revealed that gadolinium enhancement might be 
helpful in its diagnosis20). Moreover, Futagami et al. 
reported that gadolinium enhancement of the solid 
part of the tumor by MRI is a risk factor for malig-
nant transformation15). In this case, we did not per-
form CT or MRI because an emergency surgery was 
performed. Ovarian tumor torsion may affect CT 
or MR images due to the time lapse after torsion and 
disruption of blood supply21). Physicians should 
consider this point during diagnosis.
Although the incidence of torsion or rupture of 
MCTO is 0.3-16%22,23), ovarian tumor torsion in ma-
lignant transformation of MCTO has not been com-
prehensively analyzed. Therefore, we searched for 
cases of malignant transformation of MCTO present-
ing as ovarian tumor torsion in PubMed and Ichushi 
databases, the latter being a medical literature ser-
vice provided by the nonprofit organization Japan 
Medical Abstracts Society. We searched for key-
words, such as “mature cystic teratoma,” “malignant 
transformation,” and “ovarian torsion.” These 
keywords were present in seven cases, and there 
were eight cases including this case of malignant 
transformation of MCTO with torsion24-30) (Table 
2). The age of onset ranged from 38 to 77 years, 
and five of six patients were menopausal. All eight 
patients complained of lower abdominal pain and un-
derwent emergency surgery. The laterality of tor-
sion was on the right side in six patients and the left 
side in two patients. Two of eight patients had 
MCTO on both sides, and one case had SCC on the 
side without any torsion. Five of seven patients 
had increased serum tumor marker levels. The 
median diameter of the ovarian tumor on the torsion 
side was 11 cm (range, 7-11 cm). Seven of eight 
patients underwent laparotomy, and only one patient 
underwent laparoscopic surgery. Peritoneal cytolo-
gy was performed in three of eight patients ; no pa-
tients received rapid pathological diagnosis. The 
most common pathological diagnosis of malignant le-
sion was SCC (4 patients). Radical surgery for 
ovarian cancer was performed in two patients, in-
cluding ours. Except for our case, among four pa-
tients with the same prognosis, no recurrence after 
treatment has been reported.
The standard therapy for malignant transforma-
tion of MCTO includes radical surgery and adjuvant 
chemotherapy according to the staging4). In pa-
tients who choose not to have children, radical sur-
gery, such as bilateral salpingo-oophorectomy, hys-
terectomy, and comprehensive surgical staging with 
peritoneal washing cytology, omentectomy, perito-
neal biopsy, and pelvic plus para-aortic lymphade-
nectomy, is performed. After surgical staging, ad-
juvant chemotherapy with a combination of paclitaxel 
and carboplatin is performed in advanced dis-
ease. However, the prognosis of patients with ma-
lignant transformation of MCTO is worse than that 
of patients with common epithelial ovarian can-
cer4). Prognostic factors have been reported in pa-
tients with malignant transformation of MCTO. 
Age > 45 or 55 years, advanced staging, larger tu-
mor, high cancer grade, absence of hysterectomy, 
presence of residual tumor lesions, absence of adju-
vant chemotherapy, and non-platinum-based chemo-
therapy13,16,31,32) are poor prognostic factors. 
Lymphadenectomy is not a major prognostic factor 
in patients with malignant transformation of 
MCTO13,31). In this case, however, a strict follow-
up for stage IA ovarian cancer was conducted, and 
tumor recurrence in retroperitoneal lymph nodes 
developed 3 months after the initial surgery. Hur-
witz et al. reported that secondary reduction surgery 
was effective in two patients with recurrence of ma-
lignant transformation of MCTO33). In this case, 
the patient underwent adjuvant chemotherapy fol-
lowing radical surgery without residual lesions, and 
no recurrence was observed for 2 years after treat-
ment. Secondary cytoreductive surgery might be 
considered in selected patients with recurrence of 
malignant transformation of MCTO.
Although ovarian tumor torsion requires emer-
gency surgery, when physicians encounter large 
ovarian tumor torsion cases, preoperative examina-
tions should be performed, keeping the possibility of 
malignancy in mind.
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